Webinar Alert! Building Robust Potency Assays with In-Cell Western Assay Protein Expression Readouts Register Today!

Safety Assessment of Intrathecally Administered Antisense Oligonucleotides in Cynomolgus Macaques

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Safety Assessment of Intrathecally Administered Antisense Oligonucleotides in Cynomolgus Macaques

CELL & GENE | RNA | BIOLOGICS

Intrathecal administration of antisense oligonucleotides (ASOs) requires a specialized safety assessment program focused on the central nervous system (CNS). Our study designs for cynomolgus macaques prioritize the evaluation of potential neurotoxicity through a multi-faceted approach combining neurobehavioral observations, serial cerebrospinal fluid (CSF) analysis, and comprehensive terminal neurohistology. This methodology generates a robust, IND-enabling data package that characterizes the biodistribution and safety profile of ASOs delivered directly to the CNS, supporting an 18-24 month IND timeline.

    What are the primary safety endpoints for intrathecal ASO studies?

    A: Key endpoints include detailed neurobehavioral assessments, serial CSF analysis for biomarkers of inflammation and neuronal injury, and comprehensive terminal histology of the brain and spinal cord to evaluate cellular responses.

    Why are cynomolgus macaques the preferred model for this route of administration?

    A: The cynomolgus macaque CNS is a highly relevant translational model due to its anatomical similarity to humans, particularly regarding brain structure, spinal cord length, and total CSF volume, which directly impacts ASO distribution.

    How is CSF collection and analysis integrated into the study design?

    A: We perform serial CSF collections via lumbar puncture at multiple timepoints. Samples are analyzed for cell counts, total protein, and specific biomarkers to monitor for potential neuroinflammatory responses throughout the in-life phase of the study.

    What specific neurohistology techniques are employed?

    A: Our standard panel includes immunohistochemistry (IHC) for glial activation markers (Iba1 for microglia, GFAP for astrocytes), neuronal markers, and in situ hybridization (ISH) or IHC to map ASO distribution within CNS tissues.

Characterizing CNS Safety for Intrathecal ASO Programs

Direct administration of ASOs to the cerebrospinal fluid bypasses the blood-brain barrier, enabling potent target engagement within the CNS. This route also necessitates a highly specific toxicology program to de-risk potential neuroinflammation, neuronal toxicity, and unintended effects related to non-target tissue biodistribution within the CNS. A successful safety assessment hinges on a study design that can detect subtle functional changes and correlate them with analytical and histological findings.

Our approach integrates several core components to build a comprehensive safety profile:

  • Systematic Neurobehavioral Evaluation: In-life phases include structured neurological examinations and functional assessments performed by trained specialists to identify any subtle changes in motor function, coordination, or behavior.

  • Longitudinal CSF Analysis: Serial sampling provides a dynamic view of the biological response within the CNS over time, allowing for the early detection of inflammatory markers or indicators of cellular damage.

  • Comprehensive Histology: Terminal evaluation includes extensive tissue collection from multiple regions of the brain and spinal cord. In collaboration with our strategic partners in digital pathology, we conduct detailed histological analysis to identify any cellular changes or signs of toxicity.

A close-up of a multi-channel pipette dispensing liquid into a microplate in a laboratory setting, with a blue color overlay.

A close-up, detailed shot of a Sartorius Stedim Biotech BIOSTAT STR® single-use bioreactor in a laboratory setting.

Correlating Administration Kinetics with Safety Outcomes

The physical parameters of administration can influence the pharmacokinetic and safety profile of a therapeutic. For example, investigations into other advanced therapeutic modalities have shown that administration kinetics can impact vector distribution and safety, even when differences are not statistically significant (PMID: 27933307). This principle highlights the need to meticulously control and monitor administration protocols in intrathecal ASO studies to ensure data consistency and the accurate interpretation of neurotoxicology findings.

Commitment to Animal Welfare

Our programs are designed to maximize data acquisition while adhering to the highest standards of animal care.

All studies are conducted in our >100,000 sq ft GxP-compliant facility. We strictly adhere to the 3Rs principles (Reduction, Refinement, and Replacement) as a core component of our Animal Welfare strategy. This rigorous compliance framework has supported our sponsors in achieving a 100% IND success rate since 2019 (the Franklin Biolabs brand launched in 2024).

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities